Search the Newsreel

Quest Diagnostics Inc. stock underperforms Monday when compared to competitors

Shares of Quest Diagnostics Inc. (DGX) fell 1.43% on Monday, closing at $207.66. This underperformance occurred on a generally negative trading day, with both the S&P 500 Index and Dow Jones Industrial Average also declining. The stock's drop ended a two-day winning streak.

Quest Diagnostics Q2 2026 Earnings Preview — July 23, Street Expects $2.82 EPS

Quest Diagnostics is set to announce its second-quarter earnings on July 23, with analysts expecting $2.82 EPS on revenue of $2.97 billion, representing significant year-over-year growth. Despite a 100% beat rate in its last quarter, analyst EPS estimates have seen a modest downward revision …

Quest Diagnostics stock trades steady as investors weigh recent earnings and volume trends

Quest Diagnostics stock is trading steadily as investors assess its recent earnings and volume trends, driven by diagnostic testing demand and margin performance. The company's financial health is supported by resilient testing volumes, cost-management initiatives, strong cash flow, and strategic investments in technology and …

Quest Diagnostics (DGX) Expands Oncology Test Access, Is The Stock Fully Valued?

Quest Diagnostics (DGX) has expanded access to its oncology tests by integrating them into Flatiron Health’s OncoEMR platform, a move boosting investor interest. Despite recent strong stock performance, Simply Wall St assesses DGX as 5.7% undervalued with a fair value of $223.44, driven by …

Quest Diagnostics | SCHEDULE 13G/A: Others

This article is a financial filing document, specifically a SCHEDULE 13G/A, related to Quest Diagnostics. The "Others" designation suggests a filing by a category of investor other than an institutional manager, perhaps an individual or a passive investor group revealing beneficial ownership.

DGX4986719 Bond Risk Profile

This article provides a risk profile for the Quest Diagnostics Incorporated 2.8% bond, identified as DGX4986719. It highlights key metrics for assessing credit risk, such as security level, inflation protection, and issuer rating. The profile aims to help investors evaluate the bond's reliability and …

Quest Diagnostics stock holds near results driven levels

Quest Diagnostics stock performance is being evaluated based on its recent earnings metrics, including quarterly revenue of $2.62 billion, adjusted diluted EPS of $2.64, and an adjusted operating margin of 15.0%. The company's core diagnostic testing franchise is its primary earnings driver, with testing …

Digi Power X (DGX) Registration filing Summary

Digi Power X (DGX) has filed a registration summary outlining its business model, financial performance, and use of proceeds. The company develops and operates advanced data centers for sustainable energy, high-performance computing, Bitcoin mining, and AI/GPU infrastructure. DGX recently closed a $6.6 million private …

The Bull Case For Quest Diagnostics (DGX) Could Change Following Oncology Test Integration Into OncoEMR - Learn Why

Quest Diagnostics (DGX) has integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumors into Flatiron Health’s OncoEMR, making it easier for oncology clinicians to access these advanced diagnostic tests. This move supports Quest's strategy to expand high-value, data-driven testing, …

ETFs Investing in Quest Diagnostics Incorporated Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Quest Diagnostics Incorporated (DGX) stocks. It provides a detailed table including each fund's market value, weight

Quest Diagnostics stock trades steadily as investors weigh steady revenue and margin trends

Quest Diagnostics stock reflects a balance between stable revenue growth and margin pressures. Recent financial results show the company managing the transition from pandemic-related testing to routine services, maintaining mid-single-digit revenue growth and mid-teens operating margins, despite a slight decline in net income. The …

DGX.GL Bond Profile — Key Metrics

This article provides key metrics for the DGX.GL bond, issued by Quest Diagnostics, Inc. The bond has a 5.75% coupon rate and matures on January 30, 2040, with an outstanding amount of $249.24 million. Quest Diagnostics, Inc. is a diagnostic testing and information services …

Quest Diagnostics stock holds steady as diagnostics demand underpins long term growth

Quest Diagnostics stock reflects the company's significant position as a major US clinical laboratory operator, benefiting from a steady, long-term demand for diagnostic services. The company's large-scale network, operational efficiency, and role in chronic disease management and public health are key pillars of its …

Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors

Shares of Quest Diagnostics Inc. (DGX) fell 2.05% on Wednesday, closing at $201.77. This underperformance occurred despite a favorable trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average posting gains. This marked the ninth consecutive …

Quest Diagnostics tests high-range demand after pressure flips positive on 5.0M shares

DGX gained 7.6% for the week and finished just 1.3% below its 52-week high, but participation remained only modestly above its recent baseline.

Quest Diagnostics sets July 23 call for second-quarter results

Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report?

Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely (NYSE:DGX)

Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Quest Diagnostics (DGX) Q1 Earnings and Revenues Top Estimates

Quest’s (NYSE:DGX) Q1 CY2026 Sales Beat Estimates

Q4 Earnings Roundup: Quest (NYSE:DGX) And The Rest Of The Testing & Diagnostics Services Segment

Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth

Quest Diagnostics schedules April 21 earnings release, 8:30 a.m. call

Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound?

Quest’s (NYSE:DGX) Q4 CY2025: Beats On Revenue

Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

What You Need To Know Ahead of Quest Diagnostics' Earnings Release